In the subcutaneous setting with Panc02 tumors, anti-PD-1/anti-CTLA-4 treatment resulted in a synergic effect, with Slc4a4 deletion leading to tumor regression or to a static disease (Fig. 8d,e), overall offering an increased survival (Fig. 8f). The gene discussed is PDCD1; the disease is neoplasm.